摘要
目的探讨替米沙坦联合左旋氨氯地平对高血压(HT)合并2型糖尿病(T2DM)患者糖化血红蛋白水平(BbA1c)的影响。方法将高血压合并2型糖尿病患者178例随机分为观察组与对照组,每组各89例,对照组给予常规治疗加用左旋氨氯地平,观察组则在对照组的基础上加用替米沙坦治疗,治疗12周后,观察并分析两组治疗前后的血压、血脂及糖化血红蛋白的水平。结果治疗12周后,观察组总有效率为95.50%,对照组则为77.53%,两组相比较,差异有统计学意义(P<0.05);PG、HbA1c及血脂水平均较治疗前下降,差异有统计学意义(P<0.05);但组间比较,差异无统计学意义(P>0.05);而MAU水平治疗后下降较为明显,且组间比较,差异有统计学意义(P<0.05)。结论替米沙坦联合左旋氨氯地平对高血压合并2型糖尿病患者既能很好地控制血压和降低尿蛋白,又能显著改善患者糖代谢。
Objective To discuss the effect of telmisartan and levamlodipine besylate tablets in resistance on the level of the glycosylated hemoglobin in Type 2 diabetics mellitus patients with hypertension.Methods One hundred and seventy-eight cases of Type 2 diabetics mellitus patients with hypertension were chosen and randomly divided into the observation group and the control group,patients in the control group were treated by conventional therapy and added the levamlodipine besylate tablets to treat,on the basis of the control group,the observation group was treated by telmisartan,their blood pressure,blood-lipid and level of the glycosylated hemoglobin were observed and analysed after 12 weeks.Results Be treated after 12 weeks,the total effective rate of the observation group was 95.50 percent,and the control group was 77.53 percent,there were different statistical significance between them.The PG,HbA1c and blood-lipid were all lower than pretherapy,there were different statistical significance between post-treatment and pretherapy,but there were no statistical significance between the observation group and the control group.And the level of the MAU was lower obviously,there were no statistical significance between the observation group and the control group.Conclusion Type 2 diabetics mellitus patients with hypertension is treated by telmisartan and levamlodipine besylate tablets,it can control blood pressure and reduce urine protein,and also can ameliorate the patient＇s glycometabolism.
出处
《中国当代医药》
2012年第4期71-72,74,共3页
China Modern Medicine
关键词
高血压
2型糖尿病
替米沙坦
左旋氨氯地平
High blood pressure
Type 2 diabetics mellitus
Telmisartan
Levamlodipine besylate tablets
